News

Who will get cancer treatment-induced cardiotoxicity?


 

AT THE HFSA ANNUAL SCIENTIFIC MEETING

References

“There is a real opportunity here to improve the care of cancer patients and prevent heart failure,” Dr. Lenihan concluded.

He reported receiving research support from Singulex, Millenium, and Acorda as well as serving as a consultant to Onyx and Roche.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

Heart failure readmission cuts may be a phone call away
MDedge Cardiology
Heart failure hospitalizations jump after major holidays
MDedge Cardiology
Hospitalists shine in study of heart failure outcomes
MDedge Cardiology
Advanced practice registered nurses in cardiology
MDedge Cardiology
ACC project seeks to reduce heart failure, MI readmissions
MDedge Cardiology
Androgen-deprivation therapy linked to cardiac death
MDedge Cardiology
Four lifestyle changes might prevent 40% of heart failure
MDedge Cardiology
Vagal stimulation advances for heart failure
MDedge Cardiology
Annual echo an option for cardiac allograft vasculopathy screening
MDedge Cardiology
Cancer treatment–induced cardiotoxicity greatly underappreciated
MDedge Cardiology